International Lyme And Associated Diseases Society
Leaders in Lyme Disease Education and Training
Gottfried Kellerman, PhD
Saturday, October 11th, 2014
1:30 PM - 5:00 PM: Breakout E - Laboratory Advances - Moderator: Raphael B. Stricker, MD
Laboratory Assessment of Lyme Disease (4:00 PM - 4:30 PM)
Speaker Bio: Gottfried Kellermann, Ph.D. is considered an authority in the assessment of clinical conditions for which the root cause is a neuro-immune imbalance. He received his Ph.D. from the University of Mainz (Germany) and has held key positions in oncology, biochemistry and research & development at universities and in private industry.

With a Ph.D. in Human Genetics and Biochemistry, Dr. Kellermann saw the value in tests on the market to evaluate individual nervous system biomarkers, but recognized the importance of gaining a more comprehensive picture. He believed that improvements in medical care would come when the interconnectedness of the neurological, immune, and endocrine systems was recognized and applied to a care plan designed to treat the body as a whole.

To make this kind of testing available to the practitioners across the US, Dr. Kellermann opened Pharmasan Labs, Inc. in 1996. Today, this CLIA-certified lab offers a wide variety of laboratory tests to evaluate each major system in the body including assessments for neurotransmitters and related analytes in saliva and urine and other assessments in the fields of virology, immunology, and endocrinology.

Dr. Kellermann is currently the president and CEO of NeuroScience, Inc., which he founded in 2000. NeuroScience offers a line of uniquely formulated products designed to address imbalances revealed by laboratory testing. NeuroScience has partnered with Pharmasan Labs to offer novel testing that identifies imbalances in neuro-immune markers for addressing core health issues as well as to offer novel testing such as iSpot Lyme.

The partnership of these two companies led Dr. Kellermann to pioneering the concept termed the Assess and Address approach, which allows practitioners to provide personalized patient care through novel laboratory assessments and treatment strategies. Current research endeavors include the incorporation of functional genetics and further applications for iSpot technologies.